IT has been suggested that platelets may play an important role in the development of cancer metastasis; indeed, platelet aggregates around tumour cells would facilitate their arrest by the small vessels and their subsequent extravascular migration (Gasic, Gasic and Stewart, 1968; Hilgard, 1973; Wood, 1974) . This hypothesis has been further supported by the observation that drugs inhibiting platelet aggregation, such as acetylsalicylic acid and indomethacin, decreased cancer dissemination and metastasis formation in some experimental tumours (Gasic, Gasic and Murphy, 1972; Kolenich, Mansour and Flynn, 1972; Li Volsi, 1973) .
Our group has recently shown that ditazole, a new non-steroidal antiinflammatory agentwithinhibitory activity against platelet aggregation, also inhibits the fall in platelet count induced in mice by i.v. injection of cells from the Lewis lung carcinoma (3LL) (Mussoni et al., 1977) . This is an experimental tumour syngeneic with C57BL/6 mice, which metastasizes selectively to the lungs when implanted i.m. (Karrer, Humphreys and Goldin, 1967; Simpson-Herren and Lloyd, 1970) . Although platelet consumption seems not to occur during development of this tumour after i.m. implantation , an interaction between cancer cells and platelets in this model (at least in the early phases of tumour development) cannot be excluded. The aim of this study Accepted 15 September 1977 was therefore to investigate whether ditazole treatment would affect the growth and metastatic spread of 3LL cells.
Animals, materials and methods used in this study have been previously described (Poggi et al., 1976 (CMC) and given orally, from 1 h before tumour implantation until the death ofthe animals.
Control tumour-bearing animals were treated with CMC. Tumour and metastases were measured in each animal after its spontaneous death.
Exp. B.-20 pairs of 3LL-bearing mice were randomly allocated at the beginning of the experiment to receive either CMC alone or ditazole (200 mg/kg twice daily). When either animal of the pair died, its counterpart was killed.
Exp. C.-A group of 40 mice was implanted i.m. with 3LL tumour; after 11 days the tumour-bearing leg was surgically removed; the animals were then randomly allocated to receive either CMC alone or ditazole (200 mg/kg, twice daily) until each animal died spontaneously.
Exp. D.-After surgical removal of the primary tumour as in Exp. C., 15 pairs of mice were randomly allocated to receive either CMC alone or ditazole (200 mg/kg * To whom reprint requests should be addressed. The present study was based on the assumption that blood platelet aggregation by cancer cells might be of importance in the pathogenesis of metastasis in experimental tumours (Hilgard, 1973; Gasic et al., 1968; Wood, 1974 i.v. injection of 3LL cells. This drug, however, was unable to inhibit the progressive thrombocytopenia developing in mice transplanted i.m. with these cells. This lack of protective effect of ditazole was interpreted as a supporting argument for the hypothesis that platelet production might be defective in 3LL-bearing mice (Poggi et al., 1976 .
The present data indicate that normal platelet function is not a prerequisite for haematogenous metastasis in 3LL-bearing mice. This is in agreement with some recent observations by Hilgard, Heller and Schmidt (1976) who found that various inhibitors of platelet aggregation had no significant influence on spontaneous metastasis of 3LL tumour.
Using ICRF 159, a drug with antimetastatic effect in the 3LL system, Atherton, Busfield and Hellmann (1975) have shown that antimetastatic effect and inhibition of thrombus formation are not necessarily linked. Hilgard et al. (1976) have observed an increased number of lung colonies after i.v. injection of 3LL cells into mice with pharmacological suppression of platelet function. Although the differences between our control and ditazole-treated animals did not reach statistical significance, a trend toward enhanced metastasis was observed in several groups of treated animals.
Very recently, Santoro, Philpott and Jaffe (1976) provided evidence that the pharmacological inhibition of prostaglandin biosynthesis stimulates cultured tumour-cell growth, and that prostaglandin E2 inhibits tumour growth in mice bearing B-16 melanoma. It is tempting to speculate that ditazole, which is also a powerful inhibitor of prostaglandin biosynthesis (Caprino et al., 1975; Patrono, Ciabattoni and Grossi-Belloni, 1975 ) might favour the development of 3LL by reducing the availability of prostaglandins. Whether such a mechanism would counteract the possible beneficial effect of ditazole associated with inhibition of platelet aggregation is at present unknown. Further studies using platelet aggregation inhibitors not affecting prostaglandin biosynthesis would therefore seem appropriate.
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